Clinical trial
A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma
NCT00322985 · AHS Cancer Control Alberta, Other · Completed
Key facts
| NCT number | NCT00322985 |
|---|---|
| Title | A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma |
| Official title | A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma |
| Lead sponsor | AHS Cancer Control Alberta, Other |
| Collaborators | Celgene Corporation Industry Alberta Cancer Foundation |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | T-cell Lymphoma |
| Intervention type | Drug |
| Interventions | Lenalidomide |
| Enrollment | 40 |
| Start date | Jun 1, 2006 |
| Primary completion | May 1, 2014 |
| Completion | Jul 1, 2014 |
| First posted | May 9, 2006 |
| Last update posted | Mar 16, 2016 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: